{"title":"恩杂鲁胺在化疗前转移性前列腺癌中的作用","authors":"J. Zabell","doi":"10.1093/MED/9780190655341.003.0018","DOIUrl":null,"url":null,"abstract":"This chapter summarizes the findings of the landmark PREVAIL trial conducted in men with castrate-resistant prostate cancer who had received prior chemotherapy comparing enzalutamide to placebo. It demonstrated improved overall survival, radiographic progression-free survival, and time to cytotoxic chemotherapy.","PeriodicalId":435097,"journal":{"name":"50 Studies Every Urologist Should Know","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"19","resultStr":"{\"title\":\"Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy\",\"authors\":\"J. Zabell\",\"doi\":\"10.1093/MED/9780190655341.003.0018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This chapter summarizes the findings of the landmark PREVAIL trial conducted in men with castrate-resistant prostate cancer who had received prior chemotherapy comparing enzalutamide to placebo. It demonstrated improved overall survival, radiographic progression-free survival, and time to cytotoxic chemotherapy.\",\"PeriodicalId\":435097,\"journal\":{\"name\":\"50 Studies Every Urologist Should Know\",\"volume\":\"5 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"19\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"50 Studies Every Urologist Should Know\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/MED/9780190655341.003.0018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"50 Studies Every Urologist Should Know","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/MED/9780190655341.003.0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy
This chapter summarizes the findings of the landmark PREVAIL trial conducted in men with castrate-resistant prostate cancer who had received prior chemotherapy comparing enzalutamide to placebo. It demonstrated improved overall survival, radiographic progression-free survival, and time to cytotoxic chemotherapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
